<DOC>
	<DOCNO>NCT00219908</DOCNO>
	<brief_summary>The aim study determine whether therapeutic strategy combine mitoxantrone interferon beta1b delay disease progression least one point EDSS scale patient clinically active relapsing-remitting multiple sclerosis .</brief_summary>
	<brief_title>Evaluation New Therapeutic Strategy Early Active Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>age : 1845 year , Clinical disease satisfy Poser criterion ( Amdmt n°4 ) relapsingremitting disease ( Amdmt N°4 ) least 2 exacerbation within precede 12 month , leave sequela , MRI activity inclusion express least one gadoliniumenhanced lesion ( cranial MRI 0.1mmol/kg gadolinium ) , significant disability inclusion : EDSS score 2.5 5.5 ( Amdt N° 4 ) write informed consent pregnancy breastfeed use insufficiency effective contraceptive method , general immunosuppressive therapy use cyclophosphamide , mitoxantrone , total lymphoid irradiation treatment azathioprine 3 month precede study clinical relapse intensive corticosteroid treatment within 30 day precede inclusion , associate disease ( psychiatric disorder , depressive statenot control appropriate drug therapy , history heart disease inclusion examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Mitoxantrone</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Interferon beta1b</keyword>
	<keyword>Relapse</keyword>
	<keyword>MRI</keyword>
	<keyword>EDSS</keyword>
</DOC>